U.S. military veterans face racial and ethnic inequities in access to Novo Nordisk's highly in-demand drugs for diabetes and ...

In what could be a revolutionary stride in cancer care, scientists are exploring metabolism-targeting injections as a ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Deaths from cardiovascular disease have surged among adults ages 25 to 64 living in rural areas, a new study shows.

However, popular new injections like Wegovy and Ozempic may have provided an unintentional leap forward in both treatment and ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both ...

Analyzing H&H's Q3 results and investment strategy in the healthcare industry, highlighting undervaluation and raising the ...

In general, when a person prepares for a surgery, the guidance is to fast before going under anesthesia– but for patients, on gGLP-1's there may still be gastric juices, in the stomach, since the ...

Slickly designed websites. Unbelievable markdowns. A simple online search for semaglutide, the active ingredient in Ozempic or Wegovy, can lead consumers down a rabbit hole of seemingly reputable ...

Since Eli Lilly's Mounjaro and Novo Nordisk's Wegovy and Ozempic fell into shortage in late 2022, compounding pharmacies have been manufacturing their respective generics, tirzepatide and semaglutide.

Popular weight-loss drugs are helping some runners lose weight and crush PRs. Experts have some real concerns.